A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Gastrointestinal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRODIGY
- Sponsors Sanofi
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2016 Planned patient number changed from 530 to 640.
- 13 Jul 2016 Planned End Date changed from 1 Jul 2019 to 1 Jan 2020.